The FDA has approved the higher-dose formulations of Diovan HCT (valsartan/hydrochlorothiazide) for patients with high blood pressure. The medication is a combination of Diovan (valsartan), an angiotensin receptor blocker, and the diuretic hydrochlorothiazide, and is now available in 320-mg/12.5-mg and 320-mg/25-mg tablets.
Related Results
DiovanDiovanDiovan dosesFDA approves DiovanNew indicatio…
M2 PRESSWIRE-25 October 2001-NOVARTIS: Novartis receives FDA approvable letter for Diovan (valsartan) for the treatment of heart failure in patients not on an ACE inhibitor (C)1994-2001 M2 COMMUNICATIONS LTD RDATE:25102001 East Hanover, New Jersey / Basel, Switzerland — Novartis announced today that it has received an “approvable” letter from the US Food and Drug Administration (FDA) for Diovan (valsa…
Novartis received an “approvable” letter from the FDA for Diovan (valsartan) for the treatment of heart failure in patients not taking ACE inhibitors. Final approval, according to Novartis, hangs on further analysis of existing data or the submission of additional data. Diovan is a highly selective angiotensin II receptor blocker already approved for…
Related Results
DiovanDiovanDiovan dosesFDA approves DiovanNew indication for diovan
> Exforge has received regulatory approval as a treatment for patients with high blood pressure. Manufacturer Novartis AG notes that the product combines in one tablet the two most commonly prescribed hypertension medicines in their categories: Diovan and Norvasc. The new product is expected to be available in the United States in late September pending expiration of p…
Congestive heart failure (CHF), congestive cardiac failure (CCF) or just heart failure, is a condition that can result from any structural or functional cardiac disorder that impairs the ability of the heart to fill with blood or pump a sufficient amount of blood through the body. It is not to be confused w…
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the “Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second largest market” report to their offering.
No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for dev…
FOR IMMEDIATE RELEASE
June 10, 2008
WITH RECORD NUMBER OF UNINSURED,
AMERICANS TURN TO FOREIGN PHARMACIES FOR
LOWEST-PRICE PRESCRIPTION DRUGS
Consumers Find Indian Pharmacies A Cheaper Resource Than
Canadian Pharmacies, and
Discount-Priced Generic Medications Are Available
TAMPA, Florida With the number of uninsured Americans at a record 47 million, the highest number in more than 20 years*, a growing number of…
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/e5f183/the_emerging_role) has announced the addition of the “The Emerging Role of Postmarketing Clinical Research: Regulatory iss…
